UBS Group AG - ONCOCYTE CORP ownership

ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 47 filers reported holding ONCOCYTE CORP in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of ONCOCYTE CORP
ValueSharesWeighting
Q2 2023$10,057
+50.8%
43,723
+132.1%
0.00%
Q1 2023$6,668
-43.4%
18,837
-48.8%
0.00%
Q4 2022$11,781
-38.0%
36,814
+43.9%
0.00%
Q3 2022$19,000
+5.6%
25,575
+27.8%
0.00%
Q2 2022$18,000
-35.7%
20,006
+6.1%
0.00%
Q1 2022$28,000
-62.2%
18,856
-45.0%
0.00%
Q4 2021$74,000
-29.5%
34,268
+15.3%
0.00%
Q3 2021$105,000
-60.8%
29,721
-36.5%
0.00%
Q2 2021$268,000
-5.0%
46,777
-13.9%
0.00%
Q1 2021$282,000
+227.9%
54,350
+52.2%
0.00%
Q4 2020$86,000
+91.1%
35,707
+10.1%
0.00%
Q3 2020$45,000
-45.8%
32,446
-26.1%
0.00%
Q2 2020$83,000
-19.4%
43,885
+4.1%
0.00%
Q1 2020$103,000
-16.9%
42,147
-23.9%
0.00%
Q4 2019$124,000
+36.3%
55,370
+28.7%
0.00%
Q3 2019$91,000
+33.8%
43,006
+59.0%
0.00%
Q2 2019$68,000
-22.7%
27,049
+20.5%
0.00%
Q1 2019$88,000
+4300.0%
22,442
+1146.8%
0.00%
Q4 2018$2,000
+100.0%
1,800
+385.2%
0.00%
Q2 2018$1,000
-91.7%
371
-93.7%
0.00%
Q1 2018$12,000
-50.0%
5,873
+12.9%
0.00%
Q4 2017$24,000
+500.0%
5,204
+819.4%
0.00%
Q3 2017$4,000
-60.0%
566
-69.5%
0.00%
Q2 2017$10,000
+900.0%
1,854
+1717.6%
0.00%
Q1 2017$1,000
-80.0%
102
-85.4%
0.00%
Q4 2016$5,000698
+721.2%
0.00%
Q3 2016$085
-37.5%
0.00%
Q2 2016$0
-100.0%
136
+11.5%
0.00%
Q1 2016$1,0001220.00%
Other shareholders
ONCOCYTE CORP shareholders Q4 2017
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 14,716,204$20,456,0001.61%
PURA VIDA INVESTMENTS, LLC 6,022,534$8,371,0000.43%
P.A.W. CAPITAL CORP 199,700$278,0000.30%
Penbrook Management LLC 229,425$319,0000.28%
PERKINS CAPITAL MANAGEMENT INC 39,725$55,0000.05%
GSA CAPITAL PARTNERS LLP 201,047$279,0000.05%
Private Wealth Partners, LLC 150,000$209,0000.02%
Phoenix Holdings Ltd. 317,138$426,0000.02%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 255,300$355,0000.01%
ETF MANAGERS GROUP, LLC 157,933$226,0000.01%
View complete list of ONCOCYTE CORP shareholders